摘要
目的:探索草酸铂/5-FU/CF组成的FOLFOX4方案在治疗晚期胃癌中的近期疗效和毒副作用。方法:103例晚期胃癌(ⅢB～Ⅳ期)患者随机分为2组:采用PLF方案化疗组52例及采用FOLFOX4方案化疗组51例,至少治疗2周期后按WHO标准进行疗效及毒副作用评价。各组中,化疗药物用法分别为PLF方案组:CF200mg/m2d1～d5,5-FU500mg/m2d1～d5,DDP25mg/m2d1～d3;每28d为1个周期。FOLFOX4方案组:FOLFOX4方案,即OXA85mg/m2,静脉滴入2h,d1、d15;亚叶酸钙(CF)200mg/m2,静脉滴入d1、d2、d15和d16;5-FU400mg/m2,静脉推注d1、d2、d15和d16,600mg/m2,持续静脉输注22h,d1、d2、d15和d16;每28d为1个周期。结果:FOLFOX4方案组的短期有效率及1年生存率与疾病无进展时间均高于PLF方案组,并且1年生存率与疾病无进展时间的差异具有统计学意义(29.1%vs11.7%,P=0.031;10.1±3.2vs8.7±2.9,P=0.037)。结论:FOLFOX4方案是治疗晚期胃癌相对理想化疗方案,可以作为一线或二线化疗方案应用,值得进一步应用和研究。
OBJECTIVE： To investigate the short term efficacy and side effects of L-OHP combined with 5-FU and CF （FOLFOX4 regimen） in the treatment of advanced gas trie carcinoma. METHODS： A total of 103 patient with ad vancecl gastric carcinoma （ Ⅲ B-Ⅳ ） were divided into two groups： PLF regimen group had 52 cases and the FOLFOX4 regimen group had 51 cases. Then the efficacy and side effects were evaluated after 2 periods. The respective dosage of the chemotherapy medicine in each group was： PLF regimen group： CF 200 mg/m^2 d1-d5, 5-FU 500 mgm/m^2 ds,DDP 25 rag/m^2 d1-d3 ; FOLFOX4 regimen group： OXA 85 mg/m^2 ,iv gtt 2 h, d1, d15; CF 200 mg/m^2. iv gtt d1· d15 ,d16, d16; 5-FU ,100 mg/m^2, iv d1, d2, d15, d16, 600 mg/m^2 , CIV 22 h, d1 , d2 , d15, d16 ; and the chemotherapy was repeated every 28 days. RESULTS： The short-term one- year survival rate and TTP of- FOLFOX4 regimen were superiot to PLF regimen. The differenee between them had statistic significance （2.9. 1% vs 11. 7%,P=0.031;10. 1 ±3.2 vs 8.7±2.9,P= 0. 037）. CONCLUSION： The FOLFOX4 reg imen is a relatively perfect regimen in the treatment of advanced gastric carcinoma and worthy of popularizing aud applying.
出处
《中华肿瘤防治杂志》
CAS
2007年第8期610-612,共3页
Chinese Journal of Cancer Prevention and Treatment
